27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen

Nat Med. 2007 Oct;13(10):1185-92. doi: 10.1038/nm1641. Epub 2007 Sep 16.

Abstract

The cardioprotective effects of estrogen are mediated by receptors expressed in vascular cells. Here we show that 27-hydroxycholesterol (27HC), an abundant cholesterol metabolite that is elevated with hypercholesterolemia and found in atherosclerotic lesions, is a competitive antagonist of estrogen receptor action in the vasculature. 27HC inhibited both the transcription-mediated and the non-transcription-mediated estrogen-dependent production of nitric oxide by vascular cells, resulting in reduced estrogen-induced vasorelaxation of rat aorta. Furthermore, increasing 27HC levels in mice by diet-induced hypercholesterolemia, pharmacologic administration or genetic manipulation (by knocking out the gene encoding the catabolic enzyme CYP7B1) decreased estrogen-dependent expression of vascular nitric oxide synthase and repressed carotid artery reendothelialization. As well as antiestrogenic effects, there were proestrogenic actions of 27HC that were cell-type specific, indicating that 27HC functions as an endogenous selective estrogen receptor modulator (SERM). Taken together, these studies point to 27HC as a contributing factor in the loss of estrogen protection from vascular disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta, Thoracic / drug effects
  • Binding, Competitive / drug effects
  • Cardiotonic Agents / antagonists & inhibitors*
  • Cardiotonic Agents / metabolism
  • Cardiotonic Agents / pharmacology*
  • Cell Culture Techniques
  • Cell Line
  • Cells, Cultured
  • Cholesterol, Dietary / administration & dosage
  • DNA, Complementary
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Estrogens / metabolism
  • Estrogens / pharmacology*
  • Female
  • Glutathione Transferase / metabolism
  • Humans
  • Hydroxycholesterols / administration & dosage
  • Hydroxycholesterols / blood
  • Hydroxycholesterols / pharmacology*
  • Inhibitory Concentration 50
  • Injections, Subcutaneous
  • Kidney / cytology
  • Kinetics
  • Male
  • Mice
  • Mice, Knockout
  • Nitric Oxide / antagonists & inhibitors
  • Nitric Oxide Synthase Type II / antagonists & inhibitors
  • Nitric Oxide Synthase Type III
  • RNA, Messenger / metabolism
  • Receptors, Estrogen / antagonists & inhibitors
  • Receptors, Estrogen / genetics
  • Recombinant Fusion Proteins / antagonists & inhibitors
  • Selective Estrogen Receptor Modulators / administration & dosage
  • Selective Estrogen Receptor Modulators / blood
  • Selective Estrogen Receptor Modulators / pharmacology*
  • Vasodilation / drug effects

Substances

  • Cardiotonic Agents
  • Cholesterol, Dietary
  • DNA, Complementary
  • Estrogens
  • Hydroxycholesterols
  • RNA, Messenger
  • Receptors, Estrogen
  • Recombinant Fusion Proteins
  • Selective Estrogen Receptor Modulators
  • Nitric Oxide
  • 27-hydroxycholesterol
  • Nitric Oxide Synthase Type II
  • Nitric Oxide Synthase Type III
  • Nos2 protein, mouse
  • Nos3 protein, mouse
  • Glutathione Transferase